These ADCs deliver cytotoxic drugs via monoclonal antibodies, resulting in improved therapeutic efficacy (Table 1).148–151 Recently, AXL-specific single-domain antibodies (sdAbs) have demonstrated both diagnostic potential and anticancer efficacy in acute myeloid leukemia (AML).152 The fusion of sdAbs to an Fc domain also grants them new therapeutic capabilities, potentially enabling a multidrug strategy for treating cancer patients who test positive for AXL. The gene discussed is AXL; the disease is acute myeloid leukemia.